Baseline characteristics of patients enrolled in the Exenatide Study of Cardiovascular Event Lowering (EXSCEL).
<h4>Background</h4> <p>EXSCEL is a randomized, double-blind, placebo-controlled trial examining the effect of exenatide once-weekly (EQW) versus placebo on time to the primary composite outcome (cardiovascular death, nonfatal myocardial infarction or nonfatal stroke) in patients w...
Main Authors: | Mentz, R, Bethel, M, Gustavson, S, Thompson, V, Pagidipati, N, Buse, J, Chan, J, Iqbal, N, Maggioni, A, Marso, S, Ohman, P, Poulter, N, Ramachandran, A, Zinman, B, Hernandez, A, Holman, R |
---|---|
Format: | Journal article |
Language: | English |
Published: |
Elsevier
2017
|
Similar Items
-
Rationale and design of the EXenatide study of cardiovascular event lowering (EXSCEL) trial
by: Holman, R, et al.
Published: (2015) -
Effect of Once‐Weekly Exenatide on Clinical Outcomes According to Baseline Risk in Patients With Type 2 Diabetes Mellitus: Insights From the EXSCEL Trial
by: Robert J. Mentz, et al.
Published: (2018-10-01) -
Impact of exenatide on medical costs and health utilities in type 2 diabetes: experience from EXSCEL
by: Reed, S, et al.
Published: (2018) -
EXSCEL—once-weekly exenatide reduces medical resource utilization in patients with type 2 diabetes mellitus
by: Reed, S, et al.
Published: (2018) -
Within-trial evaluation of medical resources, costs, and quality of life among patients with type 2 diabetes participating in the exenatide study of cardiovascular event lowering (EXSCEL)
by: Reed, S, et al.
Published: (2019)